What are the recommended dosing guidelines for tizanidine, including initial dose, titration increments, maximum daily dose, and adjustments for elderly patients, hepatic impairment, renal impairment, and intravenous administration?

Tizanidine Dosing Guidelines

Start tizanidine at 2 mg up to three times daily in most patients, with careful dose titration over 2-4 weeks to an effective dose typically between 2-36 mg/day in divided doses, while monitoring closely for hypotension, sedation, and liver toxicity. 1

Initial Dosing

• Standard starting dose: 2 mg up to three times daily 1
• Alternative conservative approach: 2 mg once daily for 7 days, then escalate weekly 2
• The lowest starting doses are appropriate for patients with moderate or greater renal impairment 3

Dose Titration

Titration should be incremental over 2-4 weeks, as wide interpatient variability exists in effective plasma concentrations 4. The optimal dosage must be individualized through careful titration:

• Weekly dose escalation of 2-8 mg increments is reasonable 2
• Intervals between increases should be long enough to monitor for adverse effects 3
• Continue escalation until benefit occurs or side effects emerge 3

Maximum Daily Dose

The maximum daily dose is 36 mg/day 3, 5, 2, though:

• Effective doses in clinical trials ranged from 2-36 mg/day 4
• Only 21% of patients in one study tolerated the maximum 36 mg dose 5
• Mean effective doses are typically around 23 mg/day (range 6-36 mg) 2

Special Population Adjustments

Elderly Patients

Older adults require particularly cautious dosing:

• Start at 2 mg up to three times daily 1
• Elderly patients clear tizanidine four times slower than younger subjects 3
• Older adults rarely tolerate doses greater than 30-40 mg per day 1
• Monitor closely for muscle weakness, urinary dysfunction, cognitive effects, sedation, and orthostasis 1
• Elderly patients are at higher risk for adverse effects, especially when receiving higher daily doses (mean 3.00 mg/day in those with adverse effects vs 2.56 mg/day without) 6

Hepatic Impairment

Tizanidine should be used only with extreme caution in hepatic impairment 3:

• Approximately 5% of patients develop liver enzyme elevations >3x upper limit of normal 3
• Three deaths associated with liver failure have been reported 3
• Monitor aminotransferase levels at baseline, 1,3, and 6 months, then periodically thereafter 3
• Pharmacokinetic data in hepatic impairment is lacking, but the drug is hepatically metabolized 3

Renal Impairment

For creatinine clearance <25 mL/min:

• Clearance is reduced by more than 50% 3
• Reduce individual doses rather than dosing frequency during titration 3
• If higher doses are required, increase individual doses rather than frequency 3
• Monitor closely for dry mouth, somnolence, asthenia, and dizziness as indicators of potential overdose 3

Women Taking Oral Contraceptives

Clearance is reduced by approximately 50% in women on oral contraceptives 3:

• Reduce individual doses during titration 3
• Use the same monitoring approach as for renal impairment 3

Intravenous Administration

There is no FDA-approved intravenous formulation of tizanidine for routine clinical use. The evidence provided references "tizanidine (IV)" in the drug label 3, but this appears to be a labeling artifact rather than an actual IV product. All dosing recommendations are for oral administration.

Critical Safety Considerations

Hypotension Risk

• Two-thirds of patients receiving 8 mg experience a 20% reduction in blood pressure 3
• Peak hypotensive effect occurs 2-3 hours post-dose 3
• Minimize risk by careful dose titration and monitoring for orthostatic symptoms before dose advancement 3
• Avoid use with other α2-adrenergic agonists or concurrent antihypertensive therapy 3

Sedation

• 48% of patients report sedation; 10% rate it as severe 3
• Effect is dose-related: 92% drowsy at 16 mg vs 76% at 8 mg vs 35% on placebo 3
• Sedation peaks in the first week of titration 3

Drug Interactions

• Avoid concomitant CYP1A2 inhibitors (increase tizanidine levels and adverse effects, especially in elderly) 6
• Alcohol increases tizanidine AUC by 20% and Cmax by 15%, with additive CNS depression 3, 7
• Rofecoxib may potentiate adverse effects 3

Discontinuation

Taper dose slowly when discontinuing, especially after high doses or prolonged use, to minimize risk of withdrawal and rebound hypertension, tachycardia, and hypertonia 3